格利梅皮里德通过PPARγ介导的抑制机制调节LPS诱导的M1巨分极化
Wenkai Wang1, Hongrui Liu1, Pishan Yang1
1Department of Periodontology, School and Hospital of Stomatology, Cheeloo College of Medicine, Shandong University & Shandong Key Laboratory of Oral Tissue Regeneration & Shandong Engineering Research Center of Dental Materials and Oral Tissue Regeneration & Shandong Provincial Clinical Research Center for Oral Diseases, No. 44-1 Wenhua Road West, Jinan 250012, Shandong, China.
格利梅皮里德有效地抑制M1巨细胞极化,并通过向PPARγ通路并抑制IκB-p65信号传递来减少炎症. 这揭示了glimepiride的新型抗炎机制.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 巨细胞两极分化在炎症反应中起着至关重要的作用.
- M1巨细胞是促炎的,它们的失调有助于各种疾病.
- 格利梅皮里德是一种硫氨基酸,主要用于治疗2型糖尿病.
研究的目的:
- 为了研究胺对巨细胞两极分化的作用.
- 阐明基米皮里德对M1巨细胞的作用背后的分子机制.
主要方法:
- 使用脂多糖 (LPS) 来诱导RAW264.7巨细胞中的M1极化.
- 用不同度的glimepiride治疗的细胞.
- 进行了转录组测序和siRNA介导的基因沉默 (PPARγ,IκB/p65).
- 评估了M1标志物 (CD86,iNOS) 和促炎性细胞因子分泌.
主要成果:
- 格利梅皮里德显著抑制了LPS诱导的M1极化,并减少了M1标记物的表达.
- 转录组分析确定了过氧体增殖器激活受体玛 (PPARγ) 途径作为一个关键目标.
- 证实了PPARγ淘汰的glimepiride的机制涉及抑制IκB/p65信号通路.
- 格利梅皮里德减弱了促炎性细胞因子的释放.
结论:
- 格利梅皮里德通过对IκB-p65通路的PPARγ-依赖性阻塞抑制M1巨细胞的两极分化.
- 这项研究揭示了glimepiride的新型抗炎作用.
- 为glimepiride在抗炎疗法中的潜力提供了临床前证据.
更多相关视频
09:32Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
Published on: October 17, 2025
07:45Metabolic Characterization of Polarized M1 and M2 Bone Marrow-derived Macrophages Using Real-time Extracellular Flux Analysis
Published on: November 28, 2015
相关概念视频
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Dipeptidyl Peptidase 4 Inhibitors
GPCRs Regulate Adenylyl Cylase Activity
Oral Hypoglycemic Agents: Glinides
cAMP-dependent Protein Kinase Pathways
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
